Orlistat (Xenical)

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Fatty Liver

Conditions

Fatty Liver, Hepatitis

Trial Timeline

Oct 1, 2003 โ†’ Dec 1, 2006

About Orlistat (Xenical)

Orlistat (Xenical) is a approved stage product being developed by Roche for Fatty Liver. The current trial status is completed. This product is registered under clinical trial identifier NCT00160407. Target conditions include Fatty Liver, Hepatitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00160407ApprovedCompleted

Competing Products

20 competing products in Fatty Liver

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
47
Low Dose REN001 + High Dose REN001OnKure TherapeuticsPhase 1
25
GODEX + PlaceboCelltrionPhase 3
77
placebo + Omega-3 carboxylic acids + Dapagliflozin + PlaceboAstraZenecaPhase 2
52
AZ compoundAstraZenecaPhase 2
52
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + PlaceboAstraZenecaPhase 2
52
AZD7503 InterventionAstraZenecaPhase 1
33
metforminMerckPhase 2/3
65
Efinopegdutide + Semaglutide + PlaceboMerckPhase 2
52
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochlorideMerckPhase 1
33
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mLMerckPhase 2
52
LYS006 + TropifexorNovartisPhase 2
52
LJN452NovartisPhase 1
33
LCQ908 + placeboNovartisPhase 2
52
Xenical, Pegasys, CopegusRocheApproved
85
Placebo + RO5093151RochePhase 1
33
AMG 609 + PlaceboAmgenPhase 1
32
GlucagonNovo NordiskPre-clinical
22
Blood samplesNovo NordiskPre-clinical
22
NNC0194-0499 + NNC0194-0499 + NC0194-0499Novo NordiskPhase 1
32